Voyageur Pharmaceuticals Ltd.
VM.V
TSX
| 11/30/2025 | 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 86.50% | 82.92% | 50.14% | 53.55% | 22.30% |
| Depreciation & Amortization | -33.33% | -30.77% | -28.57% | -26.67% | -25.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 87.14% | 83.80% | 50.01% | 53.42% | 22.22% |
| Operating Income | -86.38% | -82.99% | -50.01% | -53.42% | -22.22% |
| Income Before Tax | -101.97% | -99.17% | -61.53% | -56.70% | -20.45% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -101.97% | -99.17% | -61.53% | -56.70% | -20.45% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -101.97% | -99.17% | -61.53% | -56.70% | -20.45% |
| EBIT | -86.38% | -82.99% | -50.01% | -53.42% | -22.22% |
| EBITDA | -86.51% | -83.14% | -50.14% | -53.55% | -22.30% |
| EPS Basic | -68.13% | -71.08% | -46.48% | -44.74% | -13.75% |
| Normalized Basic EPS | -65.52% | -74.51% | -47.73% | -46.81% | -18.37% |
| EPS Diluted | -68.13% | -71.08% | -46.48% | -44.74% | -13.75% |
| Normalized Diluted EPS | -65.52% | -74.51% | -47.73% | -46.81% | -18.37% |
| Average Basic Shares Outstanding | 20.36% | 14.67% | 10.90% | 7.99% | 5.48% |
| Average Diluted Shares Outstanding | 20.36% | 14.67% | 10.90% | 7.99% | 5.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |